Greater efforts should be made to include racial and ethnic minority patients in both clinical and translational HCC research91 (eg, genomic studies evaluating the role of the PNPLA3 gene polymorphism in NAFLD, survey studies assessing patient-reported outcomes after receipt of immunotherapy for advanced HCC, and clinical trials of biomarker development for HCC surveillance). This evidence concerns the gene PNPLA3 and hepatocellular carcinoma.